V3V.F · VITA 34 AG

-

Please sign in to comment on V3V.F

1 Comment

Admin

4 years ago

VITA 34 AG is currently in a long term uptrend where the price is trading 7.4% above its 200 day moving average.

From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.

VITA 34 AG's total revenue rose by 5.8% to $5M since the same quarter in the previous year.

Its net income has increased by 443.8% to $745K since the same quarter in the previous year.

Finally, its free cash flow fell by 55.0% to $691K since the same quarter in the previous year.

Based on the above factors, VITA 34 AG gets an overall score of 4/5.

Exchange	F
CurrencyCode	EUR
ISIN	DE000A0BL849
Sector	Healthcare
Industry	Medical Care Facilities

Target Price	6.3
Market Cap	70M
PE Ratio	22.82
Beta	0.67
Dividend Yield	None

ABOUT

VITA 34 AG

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.

V3V.F · VITA 34 AG

-

VITA 34 AG

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest VITA 34 AG using a moving average strategy